查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1401936

2030 年免疫学市场预测：按药物类别、适应症、应用和地区分類的全球分析

Immunology Market Forecasts to 2030 - Global Analysis By Drug Class (Immunosuppressants, Monoclonal Antibody, Fusion Proteins, Polyclonal Antibody and Other Drug Classes), Disease Indication, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据Stratistics MRC的数据，2023年全球免疫学市场规模为989.3亿美元，预计2030年将达到1,842.1亿美元，复合年增长率为9.5%。

免疫学是生物医学医学的一个分支，专注于免疫系统，即细胞、组织、器官和分子的复杂网络。免疫学是一个充满活力且快速发展的领域，在医学有着广泛的应用，从感染疾病管理到自体自体免疫疾病和癌症的治疗。

根据英国免疫学会统计，2018年英国约有40万人患有类风湿性关节炎。

免疫疾病盛行率增加

遗传因素和世界人口高龄化在许多免疫疾病的发展中发挥重要作用。暴露于某些环境因素，如感染疾病、污染物和毒素，可能引发或恶化免疫失调。这些疾病在免疫学市场上创造了竞争环境。结果，寻求医疗干预的患者数量增加。因此，免疫疾病的新兴市场流行对免疫学市场产生多方面的影响，推动需求、创新和研发投资。

严格规定

免疫学市场法规的製定是为了确保免疫疾病相关产品的安全性、有效性和品质。这些法规很复杂，免疫药物核准的严格监管流程可能会延迟开发并增加开发成本。监管障碍可能会限制进入市场的新疗法的数量。这可能会进一步阻碍新型免疫疗法的开拓并限制整个市场的创新。

生物技术和免疫疗法的进展

生物技术和免疫疗法的进步正在引入治疗各种免疫疾病的新策略。生物技术和免疫疗法的进步使得针对免疫疾病根本原因的专门治疗方法得以开发。此外，由于技术突破，个体化治疗技术也成为可能。除了免疫疗法的这些重要发展之外，还有细胞和基因疗法。由于这些进步，免疫学市场正在受到个人化医疗策略、标靶药物和最先进治疗的创建的推动。

与生物相似药的竞争

生物相似药是生物製药的低成本替代品，其引入可能会对市场构成威胁。日益激烈的竞争可能会导致原产免疫产品的价格压力和市场占有率下降。此外，包括小分子和基因疗法在内的替代疗法的发展也可能对传统免疫疗法构成威胁。这些新治疗方法提供了新的治疗选择，并有可能获得市场占有率。

COVID-19 的影响

COVID-19大流行对免疫学市场产生了重大影响。在大流行期间，免疫学研究已活性化，以了解新冠病毒对免疫的影响并解决其严重影响。各种 COVID-19 疫苗的成功凸显了免疫学在应对全球健康危机中的重要性，并可能导致对免疫学研究的投资和兴趣增加。此外，新型SARS-CoV-2病毒的出现使免疫学成为人们关注的焦点，并影响了免疫学市场的未来开拓。

单株抗体领域预计将成为预测期内最大的市场

由于其临床普及和高药物渗透率，单株抗体部分预计将出现良好的增长。单株抗体是实验室製造的蛋白质，可与体内的特定标靶（例如抗原）结合。单株抗体可以增强、恢復、修改和模拟免疫系统对不需要的细胞的攻击。更容易的政府核准和相对较低的风险进一步扩大了这一领域。

类风湿性关节炎领域预计在预测期内复合年增长率最高

由于老年人口的增加和研发的不断增加，预计类风湿性关节炎领域在预测期内将以最快的复合年增长率增长。类风湿性关节炎是一种影响关节的慢性发炎疾病。类风湿性关节炎是推动免疫学市场的关键因素，它专门研究免疫系统失调，导致标靶治疗、诊断工具的开拓以及对自体免疫疾病的更深入了解。

占有率最大的地区：

由于其完善的医疗基础设施，预计北美在预测期内将占据最大的市场占有率。该地区自体自体免疫和慢性发炎疾病的盛行率很高。在竞争激烈的北美市场，许多製药公司都积极从事免疫学相关药物的研究和销售。辉瑞、强生、安进、艾伯维等大公司在这一区域市场表现良好。此外，该地区患者的高诊断率可能支持该领域的扩展。

复合年增长率最高的地区：

由于自体自体免疫疾病的盛行率不断增加，预计欧洲在预测期内将经历最高的复合年增长率。该地区的主要企业包括 Genmab、Arctoris、Valo Therapeutics 和 BioNTech。根据伦敦估计，7% 的英国人口，即超过 400 万人，至少患有一种自体免疫疾病。在该地区，我们也专注于获得核准并推出治疗自体免疫疾病的药物。因此，消费者健康意识的增强和新冠肺炎 (COVID-19) 疫情正在推动欧洲市场的发展。

免费客製化服务

订阅此报告的客户可以利用以下免费自订选项之一：

  • 公司简介
    • 其他市场参与企业的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计/预测/复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 介绍
  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 应用分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球免疫学市场：依药物类别

  • 介绍
  • 免疫抑制剂
  • 单株抗体
  • 融合蛋白
  • 多克隆抗体
  • 其他药物类别

第六章全球免疫学市场：依疾病适应症

  • 介绍
  • 斑块型干癣
  • 类风湿性关节炎
  • 预防器官排斥
  • 干癣性关节炎
  • 僵直性脊椎炎
  • 发炎性肠道疾病
  • 其他疾病的适应症

第七章全球免疫学市场：依应用分类

  • 介绍
  • 医院
  • 诊所
  • 癌症研究中心和机构
  • 其他用途

第八章全球免疫学市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 中东和非洲其他地区

第九章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十章 公司简介

  • Novartis AG
  • Eli Lilly and Company
  • AbbVie Inc.
  • Janssen Global Services LLC
  • UCB SA
  • Amgen Inc.
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Aurobindo Pharma
  • F. Hoffmann-La Roche Limited
  • Astellas Pharma Inc.
  • Merck Sharp & Dohme Corporation
Product Code: SMRC24456

According to Stratistics MRC, the Global Immunology Market is accounted for $98.93 billion in 2023 and is expected to reach $184.21 billion by 2030 growing at a CAGR of 9.5% during the forecast period. Immunology is the branch of biomedical science that focuses on the study of the immune system - the complex network of cells, tissues, organs, and molecules that work together to defend the body against infections and other diseases. Immunology is a dynamic and rapidly evolving field with broad applications in medicine, ranging from infectious disease management to the treatment of autoimmune conditions and cancer.

According to British Society for Immunology, in 2018, around 400,000 people in U.K are suffering with rheumatoid arthritis.

Market Dynamics:

Driver:

Increasing prevalence of immunological disorders

Genetic factors and the aging global population play a significant role in the development of many immunological disorders. Exposure to certain environmental factors, such as infections, pollutants, and toxins, may trigger or exacerbate immunological disorders. These disorders foster a competitive environment within the immunology market. It results in a larger patient population seeking medical intervention. Thereby, the increasing prevalence of immunological disorders creates a multifaceted impact on the immunology market, driving demand, innovation, and investment in research and development.

Restraint:

Strict regulations

Regulations in the immunology market are designed to ensure the safety, efficacy, and quality of products related to immunological disorders. These regulations are complex and stringent regulatory processes for the approval of immunology drugs can result in delays and increased development costs. Regulatory hurdles may limit the number of new therapies entering the market. This could further hinder the development of novel immunological therapies and limit the overall innovation in the market.

Opportunity:

Advancements in biotechnology & immunotherapy

Novel strategies for treating a range of immunological illnesses are being introduced by developments in biotechnology and immunotherapy. They make it possible to create specialised treatments that target the underlying causes of immune diseases. Moreover, personalised treatment techniques are made possible by technological breakthroughs. Alongside these important developments in immunotherapy have been cell and gene treatments. Because of these advances, the immunology market is driven by the creation of personalized medical strategies, targeted medicines, and cutting-edge treatment methods.

Threat:

Competition from biosimilars

The introduction of biosimilars, which are lower-cost alternatives to biologic drugs, can pose a threat to the market. Increased competition may lead to pricing pressures and reduced market share for originator immunology drugs. Further, the development of alternative therapies, including small molecules and gene therapies, may also pose a threat to traditional immunology drugs. These emerging therapies could offer new treatment options and potentially capture market share.

COVID-19 Impact

The COVID-19 pandemic had a significant impact on the immunology market. During the pandemic, immunology research was increased to understand the effects of covid on immunity and cope with the severe effects of the same. The success of various COVID-19 vaccines has highlighted the importance of immunology in addressing global health crises, potentially leading to increased investment and interest in immunology research. Also, the emergence of new variants of the SARS-CoV-2 virus has kept the spotlight on immunology, which influenced future developments in immunology market.

The monoclonal antibody segment is expected to be the largest during the forecast period

Themonoclonal antibody segment is estimated to have a lucrative growth, due to the clinical efficiency of the procedure and the high prevalence of drugs. Monoclonal antibodies are proteins made in the laboratory for binding to specific targets in the body, such as antigens. They can enhance, restore, modify, or mimic the immune system's attack on unwanted cells. Their easy government approvals and relatively low levels of risk, is further pushing the segment expansion.

The rheumatoid arthritis segment is expected to have the highest CAGR during the forecast period

The rheumatoid arthritis segment is anticipated to witness the fastest CAGR growth during the forecast period, due to the growing geriatric population and rising R&D. Rheumatoid arthritis is a chronic inflammatory disorder that affects joints. Rheumatoid arthritis serves as a key driver for advancements in the immunology market by providing a specific focus on immune system deregulation, leading to the development of targeted therapies, diagnostic tools, and a deeper understanding of autoimmune diseases.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to the presence of a well-established healthcare infrastructure. The region has the high prevalence of autoimmune diseases and chronic inflammatory conditions. Numerous pharmaceutical firms are actively involved in the research and marketing of immunology medications in the fiercely competitive North American market. Pfizer, Johnson & Johnson, Amgen, AbbVie, and other significant firms are doing well in this region market. Additionally, a greater diagnosis rate among patients in the area is probably going to support the expansion of the sector.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period, owing to the increasing prevalence of autoimmune disorders. The region is home for several key players such as Genmab, Arctoris, Valo Therapeutics and BioNTech. Additionally, London estimates 7% of the U.K. population, or over 4 million individuals, have at least one autoimmune disorder. The region is also making efforts to secure approvals and launch drugs targeting autoimmune conditions. Thereon, the European market is driven by growing health-consciousness among consumers and boosted by the COVID-19 pandemic.

Key players in the market:

Some of the key players profiled in the Immunology Market include Novartis AG, Eli Lilly and Company, AbbVie Inc., Janssen Global Services LLC, UCB SA, Amgen Inc., Pfizer Inc., Bristol-Myers Squibb Company, Aurobindo Pharma, F. Hoffmann-La Roche Limited, Astellas Pharma Inc. and Merck Sharp & Dohme Corporation.

Key Developments:

In March 2023, Eli Lilly and Company received approval from the Indian regulatory agency Directorate General of Commercial Intelligence and Statistics (DGCI). This approval allowed them to launch their drug, Copellor, for the treatment of moderate-to-severe plaque psoriasis and also for psoriatic arthritis.

In March 2022, Pfizer Inc. enhanced its product offering by acquiring Arena Pharmaceuticals, a company dedicated to developing cutting-edge therapies for various immuno-inflammatory diseases.

Drug Classes Covered:

  • Immunosuppressants
  • Monoclonal Antibody
  • Fusion Proteins
  • Polyclonal Antibody
  • Other Drug Classes

Disease Indications Covered:

  • Plaque Psoriasis
  • Rheumatoid Arthritis
  • Prophylaxis of Organ Rejection
  • Psoriatic Arthritis
  • Ankylosing Spondylitis
  • Inflammatory Bowel Disease
  • Other Disease Indications

Applications Covered:

  • Hospital
  • Clinics
  • Cancer Research Centers & Institutions
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Immunology Market, By Drug Class

  • 5.1 Introduction
  • 5.2 Immunosuppressants
  • 5.3 Monoclonal Antibody
  • 5.4 Fusion Proteins
  • 5.5 Polyclonal Antibody
  • 5.6 Other Drug Classes

6 Global Immunology Market, By Disease Indication

  • 6.1 Introduction
  • 6.2 Plaque Psoriasis
  • 6.3 Rheumatoid Arthritis
  • 6.4 Prophylaxis of Organ Rejection
  • 6.5 Psoriatic Arthritis
  • 6.6 Ankylosing Spondylitis
  • 6.7 Inflammatory Bowel Disease
  • 6.8 Other Disease Indications

7 Global Immunology Market, By Application

  • 7.1 Introduction
  • 7.2 Hospital
  • 7.3 Clinics
  • 7.4 Cancer Research Centers & Institutions
  • 7.5 Other Applications

8 Global Immunology Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Novartis AG
  • 10.2 Eli Lilly and Company
  • 10.3 AbbVie Inc.
  • 10.4 Janssen Global Services LLC
  • 10.5 UCB SA
  • 10.6 Amgen Inc.
  • 10.7 Pfizer Inc.
  • 10.8 Bristol-Myers Squibb Company
  • 10.9 Aurobindo Pharma
  • 10.10 F. Hoffmann-La Roche Limited
  • 10.11 Astellas Pharma Inc.
  • 10.12 Merck Sharp & Dohme Corporation

List of Tables

  • Table 1 Global Immunology Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Immunology Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 3 Global Immunology Market Outlook, By Immunosuppressants (2021-2030) ($MN)
  • Table 4 Global Immunology Market Outlook, By Monoclonal Antibody (2021-2030) ($MN)
  • Table 5 Global Immunology Market Outlook, By Fusion Proteins (2021-2030) ($MN)
  • Table 6 Global Immunology Market Outlook, By Polyclonal Antibody (2021-2030) ($MN)
  • Table 7 Global Immunology Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 8 Global Immunology Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 9 Global Immunology Market Outlook, By Plaque Psoriasis (2021-2030) ($MN)
  • Table 10 Global Immunology Market Outlook, By Rheumatoid Arthritis (2021-2030) ($MN)
  • Table 11 Global Immunology Market Outlook, By Prophylaxis of Organ Rejection (2021-2030) ($MN)
  • Table 12 Global Immunology Market Outlook, By Psoriatic Arthritis (2021-2030) ($MN)
  • Table 13 Global Immunology Market Outlook, By Ankylosing Spondylitis (2021-2030) ($MN)
  • Table 14 Global Immunology Market Outlook, By Inflammatory Bowel Disease (2021-2030) ($MN)
  • Table 15 Global Immunology Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 16 Global Immunology Market Outlook, By Application (2021-2030) ($MN)
  • Table 17 Global Immunology Market Outlook, By Hospital (2021-2030) ($MN)
  • Table 18 Global Immunology Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 19 Global Immunology Market Outlook, By Cancer Research Centers & Institutions (2021-2030) ($MN)
  • Table 20 Global Immunology Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 21 North America Immunology Market Outlook, By Country (2021-2030) ($MN)
  • Table 22 North America Immunology Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 23 North America Immunology Market Outlook, By Immunosuppressants (2021-2030) ($MN)
  • Table 24 North America Immunology Market Outlook, By Monoclonal Antibody (2021-2030) ($MN)
  • Table 25 North America Immunology Market Outlook, By Fusion Proteins (2021-2030) ($MN)
  • Table 26 North America Immunology Market Outlook, By Polyclonal Antibody (2021-2030) ($MN)
  • Table 27 North America Immunology Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 28 North America Immunology Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 29 North America Immunology Market Outlook, By Plaque Psoriasis (2021-2030) ($MN)
  • Table 30 North America Immunology Market Outlook, By Rheumatoid Arthritis (2021-2030) ($MN)
  • Table 31 North America Immunology Market Outlook, By Prophylaxis of Organ Rejection (2021-2030) ($MN)
  • Table 32 North America Immunology Market Outlook, By Psoriatic Arthritis (2021-2030) ($MN)
  • Table 33 North America Immunology Market Outlook, By Ankylosing Spondylitis (2021-2030) ($MN)
  • Table 34 North America Immunology Market Outlook, By Inflammatory Bowel Disease (2021-2030) ($MN)
  • Table 35 North America Immunology Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 36 North America Immunology Market Outlook, By Application (2021-2030) ($MN)
  • Table 37 North America Immunology Market Outlook, By Hospital (2021-2030) ($MN)
  • Table 38 North America Immunology Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 39 North America Immunology Market Outlook, By Cancer Research Centers & Institutions (2021-2030) ($MN)
  • Table 40 North America Immunology Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 41 Europe Immunology Market Outlook, By Country (2021-2030) ($MN)
  • Table 42 Europe Immunology Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 43 Europe Immunology Market Outlook, By Immunosuppressants (2021-2030) ($MN)
  • Table 44 Europe Immunology Market Outlook, By Monoclonal Antibody (2021-2030) ($MN)
  • Table 45 Europe Immunology Market Outlook, By Fusion Proteins (2021-2030) ($MN)
  • Table 46 Europe Immunology Market Outlook, By Polyclonal Antibody (2021-2030) ($MN)
  • Table 47 Europe Immunology Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 48 Europe Immunology Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 49 Europe Immunology Market Outlook, By Plaque Psoriasis (2021-2030) ($MN)
  • Table 50 Europe Immunology Market Outlook, By Rheumatoid Arthritis (2021-2030) ($MN)
  • Table 51 Europe Immunology Market Outlook, By Prophylaxis of Organ Rejection (2021-2030) ($MN)
  • Table 52 Europe Immunology Market Outlook, By Psoriatic Arthritis (2021-2030) ($MN)
  • Table 53 Europe Immunology Market Outlook, By Ankylosing Spondylitis (2021-2030) ($MN)
  • Table 54 Europe Immunology Market Outlook, By Inflammatory Bowel Disease (2021-2030) ($MN)
  • Table 55 Europe Immunology Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 56 Europe Immunology Market Outlook, By Application (2021-2030) ($MN)
  • Table 57 Europe Immunology Market Outlook, By Hospital (2021-2030) ($MN)
  • Table 58 Europe Immunology Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 59 Europe Immunology Market Outlook, By Cancer Research Centers & Institutions (2021-2030) ($MN)
  • Table 60 Europe Immunology Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 61 Asia Pacific Immunology Market Outlook, By Country (2021-2030) ($MN)
  • Table 62 Asia Pacific Immunology Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 63 Asia Pacific Immunology Market Outlook, By Immunosuppressants (2021-2030) ($MN)
  • Table 64 Asia Pacific Immunology Market Outlook, By Monoclonal Antibody (2021-2030) ($MN)
  • Table 65 Asia Pacific Immunology Market Outlook, By Fusion Proteins (2021-2030) ($MN)
  • Table 66 Asia Pacific Immunology Market Outlook, By Polyclonal Antibody (2021-2030) ($MN)
  • Table 67 Asia Pacific Immunology Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 68 Asia Pacific Immunology Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 69 Asia Pacific Immunology Market Outlook, By Plaque Psoriasis (2021-2030) ($MN)
  • Table 70 Asia Pacific Immunology Market Outlook, By Rheumatoid Arthritis (2021-2030) ($MN)
  • Table 71 Asia Pacific Immunology Market Outlook, By Prophylaxis of Organ Rejection (2021-2030) ($MN)
  • Table 72 Asia Pacific Immunology Market Outlook, By Psoriatic Arthritis (2021-2030) ($MN)
  • Table 73 Asia Pacific Immunology Market Outlook, By Ankylosing Spondylitis (2021-2030) ($MN)
  • Table 74 Asia Pacific Immunology Market Outlook, By Inflammatory Bowel Disease (2021-2030) ($MN)
  • Table 75 Asia Pacific Immunology Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 76 Asia Pacific Immunology Market Outlook, By Application (2021-2030) ($MN)
  • Table 77 Asia Pacific Immunology Market Outlook, By Hospital (2021-2030) ($MN)
  • Table 78 Asia Pacific Immunology Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 79 Asia Pacific Immunology Market Outlook, By Cancer Research Centers & Institutions (2021-2030) ($MN)
  • Table 80 Asia Pacific Immunology Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 81 South America Immunology Market Outlook, By Country (2021-2030) ($MN)
  • Table 82 South America Immunology Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 83 South America Immunology Market Outlook, By Immunosuppressants (2021-2030) ($MN)
  • Table 84 South America Immunology Market Outlook, By Monoclonal Antibody (2021-2030) ($MN)
  • Table 85 South America Immunology Market Outlook, By Fusion Proteins (2021-2030) ($MN)
  • Table 86 South America Immunology Market Outlook, By Polyclonal Antibody (2021-2030) ($MN)
  • Table 87 South America Immunology Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 88 South America Immunology Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 89 South America Immunology Market Outlook, By Plaque Psoriasis (2021-2030) ($MN)
  • Table 90 South America Immunology Market Outlook, By Rheumatoid Arthritis (2021-2030) ($MN)
  • Table 91 South America Immunology Market Outlook, By Prophylaxis of Organ Rejection (2021-2030) ($MN)
  • Table 92 South America Immunology Market Outlook, By Psoriatic Arthritis (2021-2030) ($MN)
  • Table 93 South America Immunology Market Outlook, By Ankylosing Spondylitis (2021-2030) ($MN)
  • Table 94 South America Immunology Market Outlook, By Inflammatory Bowel Disease (2021-2030) ($MN)
  • Table 95 South America Immunology Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 96 South America Immunology Market Outlook, By Application (2021-2030) ($MN)
  • Table 97 South America Immunology Market Outlook, By Hospital (2021-2030) ($MN)
  • Table 98 South America Immunology Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 99 South America Immunology Market Outlook, By Cancer Research Centers & Institutions (2021-2030) ($MN)
  • Table 100 South America Immunology Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 101 Middle East & Africa Immunology Market Outlook, By Country (2021-2030) ($MN)
  • Table 102 Middle East & Africa Immunology Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 103 Middle East & Africa Immunology Market Outlook, By Immunosuppressants (2021-2030) ($MN)
  • Table 104 Middle East & Africa Immunology Market Outlook, By Monoclonal Antibody (2021-2030) ($MN)
  • Table 105 Middle East & Africa Immunology Market Outlook, By Fusion Proteins (2021-2030) ($MN)
  • Table 106 Middle East & Africa Immunology Market Outlook, By Polyclonal Antibody (2021-2030) ($MN)
  • Table 107 Middle East & Africa Immunology Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 108 Middle East & Africa Immunology Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 109 Middle East & Africa Immunology Market Outlook, By Plaque Psoriasis (2021-2030) ($MN)
  • Table 110 Middle East & Africa Immunology Market Outlook, By Rheumatoid Arthritis (2021-2030) ($MN)
  • Table 111 Middle East & Africa Immunology Market Outlook, By Prophylaxis of Organ Rejection (2021-2030) ($MN)
  • Table 112 Middle East & Africa Immunology Market Outlook, By Psoriatic Arthritis (2021-2030) ($MN)
  • Table 113 Middle East & Africa Immunology Market Outlook, By Ankylosing Spondylitis (2021-2030) ($MN)
  • Table 114 Middle East & Africa Immunology Market Outlook, By Inflammatory Bowel Disease (2021-2030) ($MN)
  • Table 115 Middle East & Africa Immunology Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 116 Middle East & Africa Immunology Market Outlook, By Application (2021-2030) ($MN)
  • Table 117 Middle East & Africa Immunology Market Outlook, By Hospital (2021-2030) ($MN)
  • Table 118 Middle East & Africa Immunology Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 119 Middle East & Africa Immunology Market Outlook, By Cancer Research Centers & Institutions (2021-2030) ($MN)
  • Table 120 Middle East & Africa Immunology Market Outlook, By Other Applications (2021-2030) ($MN)